Cure Parkinsons has many clinical trials underway across these different phases of clinical development. The drugs listed below are part of the clinical trials being progressed under our International Linked Clinical Trials programme (iLCT). There are now over 30 drugs already in clinical use that have been prioritised by the iLCT committee for Parkinson’s with 17 drugs already in, or about to go into, clinical trials.
The Phase 3 International Linked Clinical Trials
Exenatide (also known as Bydureon) is a clinically available and widely used drug for the treatment of type 2 diabetes. Cure Parkinson’s is investigating the repurposing of exenatide for Parkinson’s.
Exenatide and Parkinson’s
Ambroxol is used to treat respiratory conditions. Cure Parkinson’s has supported a phase ll repurposing trial and is supporting a further phase III clinical trial which is being designed to test the efficacy of ambroxol in slowing the progression of Parkinson’s.
Ambroxol and Parkinson’s
The Phase 2 International Linked Clinical Trials
This medication is already in use as a treatment for inflammation and the AZA-PD Study is looking at dampening down the immune response as a way of slowing the progression of Parkinson’s. The trial is being conducted in Cambridge (UK) and is supported by Cure Parkinson’s.
Read more about Azathioprine and Parkinson’s
Anle138b is a promising drug that targets the toxic accumulation of alpha-synuclein with the aim of alleviating neurodegenerative symptoms. This study is now recruiting people with Parkinson’s to participate.
Find out more here.
A similar drug to exenatide, this drug is designed to access the brain better – NLY-01 was highly prioritised by the International Linked Clinical Trials (iLCT) committee in 2017. Similar drugs to NLY-01 already approved for the treatment of type 2 diabetes include exenatide, lixisenatide, and liraglutide – all three of these drugs have been or are being trialled in Parkinson’s through the Cure Parkinson’s iLCT programme. We are delighted to see Neuraly move this drug into a phase 2 clinical trial in the U.S.
Find out more here.
This drug is used in the treatment of gallstones and has been determined to have beneficial effects on mitochondrial function in models of Parkinson’s. The UP study – UDCA in Parkinson’s, supported by Cure Parkinson’s and conducted in Sheffield and London (UK), has now finished and we are awaiting results.
Read more about UDCA and Parkinson’s
Deferiprone is an iron chelator – a class of medication used to reduce iron levels in the body. There is evidence that reducing iron in the brain can be beneficial for Parkinson’s.
Read more about Deferiprone and Parkinson’s
The Australian Parkinson’s Mission (APM) is a 5-year clinical trial project funded by the Australian Federal Government. The first trial is testing three drugs that have been prioritised by the International Linked Clinical Trials initiative, comparing them with a single placebo. Further APM trials are being set up.
Read more about the APM